Rejenevie Therapeutics

Executive Summary

Rejenevie Therapeutics is a private, early-stage biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company is developing cell culture-based therapeutics aimed at immune restoration to treat age-related diseases. Its current offering is administered at a clinic in the Bahamas in partnership with the Okyanos Center for Regenerative Medicine, suggesting a focus on direct-to-patient services or early clinical access. While the company is in a nascent stage with no disclosed pipeline, funding, or valuation, its approach addresses a large and growing market for age-related conditions. The lack of public data on clinical progress or financing makes it difficult to assess the technology's maturity, but the collaboration with a clinical center indicates some level of operational activity. Rejenevie operates in the competitive cell and gene therapy space, where differentiation will depend on clinical validation and scalability.

Upcoming Catalysts (preview)

• Q4 2026Initial Clinical Data Readout from Bahamian Clinic60% success
• Q2 2026Series A Funding Announcement50% success
• TBDRegulatory Milestone or IND Filing30% success